 |
77 Diseases |  |
69 Trials |
|
69 Trials |  |
4434 News |  |
| «12...910111213141516171819...4546» |
- || tenofovir disoproxil fumarate / Generic mfg.
Review, Journal: Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection. (Pubmed Central) - Jun 3, 2021
However, remdesivir, a nucleotide analog that acts as reverse-transcriptase inhibitor, which was tested early during the pandemic because of its wide range of antiviral activity against several RNA viruses and its safety profile, is currently the only antiviral medication approved for COVID-19...No data on tenofovir's efficacy in coronavirus infections other than COVID-19 are currently available, although information relating to SARS-CoV-2 infection is starting to come out. Here, we review the currently available evidence on tenofovir's efficacy against SARS-CoV-2.
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Clinical, Review, Journal: Clinical Management of COVID-19: A Review of Pharmacological Treatment Options. (Pubmed Central) - Jun 3, 2021
Drugs such as lopinavir/ritonavir, umifenovir, favipiravir, anakinra, chloroquine, hydroxychloroquine, tocilizumab, interferons, tissue plasminogen activator, intravenous immunoglobulins, and nafamosat have been used off-label with mixed therapeutic results...The lack of standard treatment for COVID-19 has made it difficult to interpret results from most of the published studies due to the risk of attribution error. The long-term effects of drugs can only be assessed after several years of clinical experience; therefore, the efficacy and safety of current COVID-19 therapeutics should continue to be rigorously monitored as part of post-marketing studies.
- hydroxychloroquine / Generic mfg.
[VIRTUAL] COVID-19 PNEUMONIA IN CHILDREN () - Jun 2, 2021 - Abstract #ESPID2021ESPID_1267;
COVID-19 treatment in children is a clinical challenge and trials in treatment management are still needed, especially in paediatrics. Signs of severe and critical illness are crucial to define the best therapeutic approach.
- zidovudine / Generic mfg.
[VIRTUAL] MEASLES PNEUMONIA IN AN IMMUNOCOMPROMISED CHILD () - Jun 2, 2021 - Abstract #ESPID2021ESPID_1223;
On the 6th day of in-patient treatment, the girl was transferred to the infectious department, on the 13 th day she was discharged home (received antiretroviral therapy, cefixime, co-trimoxazole)...Measles pneumonia in immunocompromised HIV-infected patients has viral-bacterial etiology and requires aggressive combination of antibiotic therapy in combination with enhanced antiretroviral therapy. Protective immunity against measles has been studied but still not fully understood for HIV-infected patients.
- | sirolimus / Generic mfg., ritonavir / Generic mfg.
Journal: Can pharmaceutical drugs used to treat Covid-19 infection leads to human health risk? A hypothetical study to identify potential risk. (Pubmed Central) - Jun 1, 2021
The presence of background contaminants in contaminated water does not show any influence on the observed risk estimates as indicated by low HQ values (<1). Regular monitoring of pharmaceutical drugs in aquatic environment needs to be carried out to reduce the adverse effects of pharmaceutical drugs on human health.
- || hydroxychloroquine / Generic mfg.
Clinical, Journal: Comorbidities and Factors Determining Medical Expenses and Length of Stay for Admitted COVID-19 Patients in Korea. (Pubmed Central) - May 28, 2021
In summary, contrary to popular beliefs, medical expenses and length of hospitalization were mostly influenced by age, and not by comorbidities, anti-viral, or anti-hypertensive drugs. Thus, responses should focus on infection prevention and control rather than clinical countermeasures.
- || hydroxychloroquine / Generic mfg., favipiravir / Generic mfg.
Clinical, Journal: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. (Pubmed Central) - May 27, 2021
Time to clinical recovery in the Favipiravir group was similar to Lopinavir/Ritonavir group (HR = 0.94, 95% CI 0.75 - 1.17) and likewise the changes in the daily SpO after discontinuation of supplemental oxygen (p = 0.46) Adding Favipiravir to the treatment protocol did not reduce the number of ICU admissions or intubations or In-hospital mortality compared to Lopinavir/Ritonavir regimen. It also did not shorten time to clinical recovery and length of hospital stay.
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Clinical, Review, Journal: COVID-19: breaking down a global health crisis. (Pubmed Central) - May 27, 2021
In response to the COVID-19 pandemic, countries and stakeholders have taken varying precautions to combat and contain the spread of the virus and dampen its collateral economic damage. This review paper aims to synthesize the impact of the virus on a global, micro to macro scale.
- lopinavir/ritonavir / Generic mfg.
[VIRTUAL] Caregivers perception on paedriatic lopinavir/ritonavir formulations for HIV-infected children at Baylor Clinic, Mwanza, Tanzania () - May 27, 2021 - Abstract #IASHIV2021IAS_HIV_1347;
Further studies with large sample size to assess perception and reasons for preference of LPV/r formulations. Strengthen supply chain management for child- friendly pediatric formulations to avoid stock out and unnecessary changing of formulations in future.
- lopinavir/ritonavir / Generic mfg.
[VIRTUAL] Low viral suppression in children < 3 years old on two protease inhibitor formulations in Kenya, 2015-2019 () - May 27, 2021 - Abstract #IASHIV2021IAS_HIV_1314;
However, younger children < 3 years have sub-optimal VLS regardless of LPV/r pellets or syrup use. Findings call for use of optimal regimens and strengthening key interventions and strategies such as enhanced adherence counseling and psychosocial support for caregivers to improve VLS in younger children which are easier to administer and more palatable for this age group.
- Tivicay (dolutegravir) / ViiV Healthcare
[VIRTUAL] Effect of dolutegravir on folate and vitamin B12 status among HIV-infected children and adolescents in the ODYSSEY trial () - May 27, 2021 - Abstract #IASHIV2021IAS_HIV_1079;
Vitamin B12 levels were similar in both arms. These results suggest any increased risk of NTDs in infants conceived on DTG is unlikely to be due to DTG causing decreased folate and vitamin B12 levels.
- Tivicay (dolutegravir) / ViiV Healthcare
[VIRTUAL] Weight gain in children and adolescents on dolutegravir vs standard of care in the ODYSSEY trial () - May 27, 2021 - Abstract #IASHIV2021IAS_HIV_1032;
Differences between arms in weight, height and BMI were small and stabilized before 2 years, with few becoming newly overweight or obese in either arm. DTG-based ART was not associated with excessive weight gain in children and adolescents.
- Aikening (albuvirtide) / Frontier Biotechnologies
[VIRTUAL] Efficacy and safety of long acting HIV fusion inhibitor albuvirtide in treatment-experienced HIV-1 infected patients: week 48 analysis from the randomized controlled phase 3 TALENT study () - May 27, 2021 - Abstract #IASHIV2021IAS_HIV_880;
P3
DTG-based ART was not associated with excessive weight gain in children and adolescents. Two-drug regimen of albuvirtide in combination with lopinavir/ritonavir was well tolerated and non-inferior to the standard second-line three-drug regimen at 48 weeks.
- lopinavir/ritonavir / Generic mfg.
[VIRTUAL] Assessing parental choice of lopinavir/ritonavir granules intake to improve child adherence at Baylor-Mwanza, Tanzania () - May 27, 2021 - Abstract #IASHIV2021IAS_HIV_808;
Although the suggested first option was mixing with food, the preferred option of administering LPV/r granules was with water. The majority of the caregivers well accepted the new administration route, being vomiting and dose size the biggest challenges observed.
- Tivicay (dolutegravir) / ViiV Healthcare
[VIRTUAL] Dolutegravir-based regimen is associated with metabolic syndrome components among persons with HIV in sub-Saharan Africa () - May 27, 2021 - Abstract #IASHIV2021IAS_HIV_721;
Our study showed that PWH on DTG-based regimen tends to have higher BP, WC and deranged lipids associated with metabolic syndrome. However, there is a need for more robust study designs to determine the real effect of INSTI on metabolic syndrome and its components in SSA.
- || ribavirin / Generic mfg.
Clinical, Journal: A Case Study Supporting Lack of SARS-CoV-2 Spread to a 3-Month Old Infant Through Exclusive Breastfeeding. (Pubmed Central) - May 26, 2021
Our findings suggest that breastfeeding may be less of a risk than anticipated. Additional research is needed to explore this possibility.
- | hydroxychloroquine / Generic mfg., ritonavir / Generic mfg.
Journal: Anti-malarial Drugs are Not Created Equal for SARS-CoV-2 Treatment: A Computational Analysis Evidence. (Pubmed Central) - May 25, 2021
Our data suggest that hydroxychloroquine may exert additional direct antiviral activity compared to chloroquine. In the absence of clinical studies comparing the efficacy of these two compounds, hydroxychloroquine may offer additional effects and may be considered as first choice.
- || hydroxychloroquine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Clinical, Retrospective data, Journal: Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients. (Pubmed Central) - May 25, 2021
Triple therapy is associated with an increase in the incidence of AKI in non-ICU COVID-19 patients. The underlying mechanisms may comprise a CYP3A4 enzyme interaction, and may be relevant for any future therapy combining hydroxychloroquine with antiviral agents.
- || chloroquine phosphate / Generic mfg., hydroxychloroquine / Generic mfg., ritonavir / Generic mfg.
Review, Journal: The Rise and Fall of Chloroquine/Hydroxychloroquine as Compassionate Therapy of COVID-19. (Pubmed Central) - May 25, 2021
Furthermore, the review presents a critical analysis of the clinical trial findings and also provides an insight into the dynamically changing decision on the authorization and withdrawal of HCQ as anti-COVID-19 therapy by the U.S. FDA and the WHO. Ultimately, our study necessitates an evidenced-based treatment protocol to confront the ongoing COVID-19 pandemic and not the mere observational study that mislead the public healthcare system, which paralyzes the entire world.
- || Ilaris (canakinumab) / Novartis
Clinical, Journal: Efficacy of canakinumab in mild or severe COVID-19 pneumonia. (Pubmed Central) - May 22, 2021
In hospitalized adult patients with mild or severe non ICU COVID-19, canakinumab could be a valid therapeutic option. Canakinumab therapy causes rapid and long-lasting improvement in oxygenation levels in the absence of any severe adverse events.
- | hydroxychloroquine / Generic mfg., dexamethasone / Generic mfg.
Journal: New challenges to fighting COVID-19: Virus variants, potential vaccines, and development of antivirals. (Pubmed Central) - May 22, 2021
Nevertheless, antivirals including monoclonal antibodies and oral medicines need to be developed in light of uncertainties with regard to vaccination. In the battle between humans and SARS-CoV-2, the speed with which we fight the virus, and especially its emerging variants, is the key to winning.
- | Journal: In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel-A Drug Antitarget. (Pubmed Central) - May 22, 2021
Favipiravir's small size and relatively paucity of simultaneous interactions may confer reduced hERG liability compared to the other drugs. Experimental structure-function studies are now warranted to validate these observations.
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Actemra IV (tocilizumab) / Roche, JW Pharma, Kineret (anakinra) / SOBI
[VIRTUAL] SAFETY AND EFFICACY OF ANAKINRA IN SEVERE SARS-COV2 INFECTION (COVID19) AT A TERTIARY HOSPITAL (Posters Viewing) - May 21, 2021 - Abstract #EULAR2021EULAR_3530;
Anakinra in severe SARS-CoV-2 infection offers respiratory improvement and partial lab tests improvement. No adverse effects were observed.
- | Nexavar (sorafenib) / Bayer, Amgen
Preclinical, Journal: In vitro effectivity of three approved drugs and their synergistic interaction against Leishmania infantum. (Pubmed Central) - May 21, 2021
Each drug when used as monotherapy against Leishmania spp. was effective, but the combination therapy was more effective than the individual drugs due to the additive or synergistic effects.
- | ribavirin / Generic mfg., ritonavir / Generic mfg.
Journal: Inhibition effects of eight anti-coronavirus drugs on glycosides metabolism and glycosidases in human gut microflora. (Pubmed Central) - May 21, 2021
However, for the inhibition of darunavir and chloroquine on the metabolism of quercetrin, there was no correlation between gut microflora and α-rhamnosidase system. Assessing the risk of HDI mediated by glycosidases in gut microflora may be conducive to the safety and efficacy of combining traditional herbal and Western medicine for the treatment of patients with Covid-19.
- || Clinical, Journal: Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study. (Pubmed Central) - May 21, 2021
Antithrombotics, antibiotics, H2 receptor antagonists, and corticosteroids were often used as adjunctive treatments. Research is needed on the comparative risk and benefit of these treatments in the management of covid-19.
- || hydroxychloroquine / Generic mfg., ritonavir / Generic mfg.
Retrospective data, Review, Journal, HEOR: Comparative Effectiveness of Pharmacological Interventions for Covid-19: A Systematic Review and Network Meta-Analysis. (Pubmed Central) - May 21, 2021
Corticosteroids significantly reduced the mortality rate also when compared to hydroxychloroquine (RR 0.83, 95%CI 0.74, 0.94; moderate certainty of evidence)...The combination of lopinavir and ritonavir proved to reduce SAEs when compared to plasma (RR 0.49, 95%CI 0.25, 0.95; high certainty of evidence)...Remdesivir appeared to be a safer option than SC or placebo, while plasma was associated with safety concerns. These preliminary evidence-based observations should guide clinical practice until more data are made public.
- || lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: results of a large multicenter study. (Pubmed Central) - May 20, 2021
These preliminary evidence-based observations should guide clinical practice until more data are made public. No abstract available
- || hydroxychloroquine / Generic mfg.
Review, Journal: Assessment and management of asymptomatic COVID-19 infection: A Systematic Review. (Pubmed Central) - May 20, 2021
There are no studies of adequate design to make this decision. It has been shown that most asymptomatic individuals who were followed have recovered, but this cannot be attributed to standard treatment.
- | ritonavir / Generic mfg.
Journal: Genomic instability in people living with HIV. (Pubmed Central) - May 20, 2021
The CD4/CD8 ratio affects the numbers of nuclear buds and binucleated cells. These findings are pertinent to mechanisms of damage and possible strategies to mitigate carcinogenesis in PLWH.
- | hydroxychloroquine / Generic mfg.
Retrospective data, Journal: Dynamic Changes in Liver Function Tests and Their Correlation with Illness Severity and Mortality in Patients with COVID-19: A Retrospective Cohort Study. (Pubmed Central) - May 20, 2021
COX analysis revealed that ALT > 2 ULN (HR=7.0, p=0.011), AST > 2 ULN (HR=34.7, p 2 ULN (HR=54.6, p < 0.001) were associated with a higher mortality. Dynamic abnormalities of liver function parameters are common in hospitalized patients with COVID-19, and associated with illness severity and mortality.
- || hydroxychloroquine / Generic mfg.
Clinical, Journal: Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Registry (Pubmed Central) - May 20, 2021
Patients with COVID-19 hospitalized in Spain are mostly severe cases, as one in three patients developed respiratory distress and one in five patients died. These findings confirm a close relationship between advanced age and mortality.
- || Clinical, Journal: Timing, Dosage, and Adherence of Antiretroviral Therapy and Risk of Osteoporosis in Patients With Human Immunodeficiency Virus Infection in Taiwan: A Nested Case-Control Study. (Pubmed Central) - May 20, 2021
In conclusion, history of ART, current exposure to ART, higher cumulative DDDs, and higher ART adherence were associated with an increased risk of osteoporosis. Furthermore, NRTI- and PI-containing regimens and high doses of PIs lopinavir-ritonavir combination may be associated with an increased risk of osteoporosis in patients with HIV infection in Taiwan.
- | hydroxychloroquine / Generic mfg.
Journal: EVOLUCIÓN DEL INTERVALO QTC EN PACIENTES CON INFECCIÓN SARS-COV-2 TRATADOS CON FARMACOS ANTIVIRALES. (Pubmed Central) - May 20, 2021
The use of antivirals caused an increase on the QTc interval after 72 hours of treatment, being the QTc long in 36.3% of the patients, although no arrhythmic events were observed. The use of hydroxychloroquine and antivirals requires active QTc monitoring and it is recommended to discontinue treatment if QTc >500ms.
- lopinavir/ritonavir / Generic mfg.
[VIRTUAL] Pharmacokinetics of lopinavir/ritonavir in hospitalised patients with COVID-19 not requiring critical care () - May 20, 2021 - Abstract #ECCMID2021ECCMID_2769;
- | ritonavir / Generic mfg.
Journal: Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings. (Pubmed Central) - May 20, 2021
Moreover, the results show concurrence with Nelfinavir, Lopinavir and Ritonavir which have shown significant inhibition in in vitro studies. Therefore, we conclude that Tenofovir and Terlipresssin might also show protease inhibition but are still open to clinical validation in case of SARS-CoV 2 treatment.Communicated by Ramaswamy H. Sarma.
- ritonavir / Generic mfg.
[VIRTUAL] Predictors of Severe Covid-19 in Kidney Transplant Recipients in the First and Second Waves: Analysis of the Spanish Registry () - May 18, 2021 - Abstract #ATC2021ATC_1986;
Over a thousand KT have suffered Covid-19 in Spain with a high mortality rate in the first and second waves, mainly related with age, pneumonia and recent transplantation. The interaction between age and time after transplant has to be considered when selecting recipients in the Covid-19 pandemic.
- Actemra IV (tocilizumab) / Roche, JW Pharma
[VIRTUAL] Risk Factors for Mortality in Kidney Transplant Patients Infected by Sars-cov-2 in South of Spain () - May 18, 2021 - Abstract #ATC2021ATC_1300;
Risk factors are patient age, time after KT, baseline renal function, the presence of pneumonia, as well as higher CRP levels at the time of diagnosis. More experience is needed to optimize our protocols and therapy for Covid-19 in KT.
- ||| Aikening (albuvirtide) / Frontier Biotechnologies
Clinical, P3 data, P3 data: top line, Journal, Head-to-Head: Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study. (Pubmed Central) - May 15, 2021
P3
The TALENT study is the first phase 3 trial of an injectable long-acting HIV drug. This interim analysis indicates that once-weekly albuvirtide in combination with ritonavir-boosted lopinavir is well tolerated and non-inferior to the WHO-recommended second-line regimen in patients with first-line treatment failure.
- || zidovudine / Generic mfg.
Clinical, Journal: Evolution of blood lipids and risk factors of dyslipidemia among people living with human immunodeficiency virus who had received first-line antiretroviral regimens for 3 years in Shenzhen. (Pubmed Central) - May 15, 2021
This interim analysis indicates that once-weekly albuvirtide in combination with ritonavir-boosted lopinavir is well tolerated and non-inferior to the WHO-recommended second-line regimen in patients with first-line treatment failure. The incidence of dyslipidemia varies with different antiretroviral regimens, with TDF + 3TC + EFV having lower risk for dyslipidemia than the other first-line free antiretroviral regimens in China.
- | lopinavir/ritonavir / Generic mfg.
Journal: Lichen planus after SARS-CoV-2 infection treated with lopinavir/ritonavir. (Pubmed Central) - May 15, 2021
The incidence of dyslipidemia varies with different antiretroviral regimens, with TDF + 3TC + EFV having lower risk for dyslipidemia than the other first-line free antiretroviral regimens in China. No abstract available
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Clinical, Journal: COVID-19 in lung transplant recipients: A multicenter study. (Pubmed Central) - May 14, 2021
In this multi-center LTR cohort, SARS-Cov-2 presented with high mortality. Additionally, the severity of disease on presentation predicted subsequent mortality.
- || lopinavir/ritonavir / Generic mfg.
Review, Journal: Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment. (Pubmed Central) - May 14, 2021
We reviewed data from the literature about LPV/r treatment and SARS-CoV-2 infection, mainly focused on the efficacy and safety of this drugs for COVID-19 treatment. We can conclude that although up to date no clear benefit has been observed with the LPV/r treatment beyond standard care, its efficacy against SARS-COV-2 infection deserves further evaluations, particularly during the very early phase of the disease.
- | ritonavir / Generic mfg.
Journal: Phytochemicals against SARS-CoV as potential drug leads. (Pubmed Central) - May 14, 2021
In total, seventy-eight phytochemicals with anti-CoV activity against different strains in cellular assays, were selected for this computational study, and compared with two existing repurposed FDA-approved drugs: lopinavir and ritonavir. This review brings insights in the potential application of phytochemicals and their derivatives, which could guide researchers to develop safe drugs against SARS-CoV-2.
- || lopinavir/ritonavir / Generic mfg.
Clinical, Review, Journal: Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. (Pubmed Central) - May 14, 2021
Lopinavir/ritonavir is effective in the treatment of COVID-19, and this combination should be further assessed in RCT studies. In addition, when we analyzed the differences in age and sex, we found that the differences were statistically significant in the safety and effectiveness of lopinavir/ritonavir in patients with COVID-19, and both of these factors played a significant role in the trial.
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Clinical, Observational data, Retrospective data, Journal: Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience. (Pubmed Central) - May 14, 2021
Adjuvant iron chelator (deferasirox - marketed as Exjade) was associated in 11 patients who had ferritin serum levels above 1000 ng/mL...The off-label use of TCZ in patients with severe or critically ill form of SARS-CoV-2 infection had good results in our study.Off-label use of TCZ in severe and critical cases of COVID-19 pneumonia is effective in managing the "cytokine storm." Better outcomes were noted in younger patients. Associated adjuvant iron chelators may contribute to a good outcome and needs to be confirmed in larger studies.
- || hydroxychloroquine / Generic mfg., ritonavir / Generic mfg.
Review, Journal: Current COVID-19 treatments: Rapid review of the literature. (Pubmed Central) - May 14, 2021
However, a combination of therapies administered at different stages of infection may provide some benefit. This conclusion is reflected in the limited effects of these treatments in previous human coronaviruses.
- | NN1213 / Novo Nordisk
Enrollment closed: EIT: Early Infant HIV Treatment in Botswana (clinicaltrials.gov) - May 14, 2021
P2/3, N=75, Active, not recruiting, Sponsor: Harvard School of Public Health
This conclusion is reflected in the limited effects of these treatments in previous human coronaviruses. Recruiting --> Active, not recruiting
- Zarzio (filgrastim biosimilar) / Novartis
[VIRTUAL] CHARACTERISTICS AND OUTCOME OF ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND COVID 19 INFECTION IN THE FIRST VS. SECOND EPIDEMIC WAVE IN SPAIN: A STUDY FROM THE PETHEMA AND GETH GROUPS () - May 13, 2021 - Abstract #EHA2021EHA_846;
Eleven pts were receiving immunosuppressive drugs at COVID infection (fludarabine in 6, among others)...COVID19 therapy was different in the two periods, with significantly higher use of hydroxychloroquine, remdesivir and lopinavir-ritonavir in the first wave and corticosteroids in the second wave...The poor outcome of COVID infection makes vaccination a priority for ALL patients in this pandemic period. Supported in part by 2017 SGR288 (GRC) Generalitat de Catalunya and “la Caixa” Foundation.
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Clinical, Observational data, Journal: Risk factors for unfavorable outcome and impact of early post-transplant infection in solid organ recipients with COVID-19: A prospective multicenter cohort study. (Pubmed Central) - May 13, 2021
Four baseline features were identified as independent predictors of intensive care need or death: advanced age, high respiratory rate, lymphopenia, and elevated level of lactate dehydrogenase. In summary, this study presents comprehensive information on characteristics and complications of COVID-19 in hospitalized SOTRs and provides indicators available upon hospital admission for the identification of SOTRs at risk of critical disease or death, underlining the need for stringent preventative measures in the early post-transplant period.